TY - JOUR AU - Wheeler, Stephanie B AU - Reeder-Hayes, Katherine AU - Meyer, Anne-Marie PY - 2012 TI - A balancing act for breast cancer? Everolimus for hormone receptor positive patients JF - Translational Cancer Research; Vol 1, No 2 (August 01, 2012): Translational Cancer Research Y2 - 2012 KW - N2 - Recent results from a Phase III randomized trial comparing everolimus [a mammalian target of rapamycin (mTOR) inhibitor] plus exemestane versus placebo plus exemestane provide encouraging evidence of a new option for treatment of advanced, hormone receptor positive (HR+) breast cancer (1). Oral endocrine therapy (ET) is the first line therapeutic strategy of choice for most women with metastatic HR+, Her2 negative breast cancer (2). UR - https://tcr.amegroups.org/article/view/414